Deletion of the BDNF Truncated Receptor TrkB.T1 Delays Disease Onset in a Mouse Model of Amyotrophic Lateral Sclerosis by Yanpallewar, Sudhirkumar U. et al.
Deletion of the BDNF Truncated Receptor TrkB.T1 Delays
Disease Onset in a Mouse Model of Amyotrophic Lateral
Sclerosis
Sudhirkumar U. Yanpallewar, Colleen A. Barrick, Hannah Buckley, Jodi Becker, Lino Tessarollo*
Neural Development Section, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America
Abstract
Brain Derived Neurotrophic Factor (BDNF) exerts strong pro-survival effects on developing and injured motoneurons.
However, in clinical trials, BDNF has failed to benefit patients with amyotrophic lateral sclerosis (ALS). To date, the cause of
this failure remains unclear. Motoneurons express the TrkB kinase receptor but also high levels of the truncated TrkB.T1
receptor isoform. Thus, we investigated whether the presence of this receptor may affect the response of diseased
motoneurons to endogenous BDNF. We deleted TrkB.T1 in the hSOD1
G93A ALS mouse model and evaluated the impact of
this mutation on motoneuron death, muscle weakness and disease progression. We found that TrkB.T1 deletion significantly
slowed the onset of motor neuron degeneration. Moreover, it delayed the development of muscle weakness by 33 days.
Although the life span of the animals was not affected we observed an overall improvement in the neurological score at the
late stage of the disease. To investigate the effectiveness of strategies aimed at bypassing the TrkB.T1 limit to BDNF
signaling we treated SOD1 mutant mice with the adenosine A2A receptor agonist CGS21680, which can activate
motoneuron TrkB receptor signaling independent of neurotrophins. We found that CGS21680 treatment slowed the onset
of motor neuron degeneration and muscle weakness similarly to TrkB.T1 removal. Together, our data provide evidence that
endogenous TrkB.T1 limits motoneuron responsiveness to BDNF in vivo and suggest that new strategies such as Trk
receptor transactivation may be used for therapeutic intervention in ALS or other neurodegenerative disorders.
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Introduction
Neurotrophins are potent regulators of survival and function of
mammalian nervous system neurons [1,2,3]. These functions are
mediated by their binding to the Trk tyrosine kinase receptors and
p75, a member of the tumor necrosis factor receptor family. Trk
genes include three members, TrkA which binds the neurotrophin
Nerve Growth Factor (NGF), TrkB the main receptor for BDNF
and Neurotrophin4/5 (NT4/5), and TrkC the preferred receptor
for Neurotrophin3 (NT3) [4,5,6]. The TrkB and TrkC loci, in
addition to the full-length kinase receptors, can generate, by
alternative splicing, truncated receptors lacking the canonical
intracellular tyrosine kinase domain [reviewed in [6]]. However,
how these receptor isoforms coordinate cellular or systemic
neurotrophin responses is still poorly understood. Gene targeting
experiments in mouse deleting all, or a specific isoform, of the
TrkB or TrkC gene have shown that the full-length Trk kinase
receptors have the strongest prosurvival effect on specific
populations of the nervous system [7,8,9,10]. Truncated receptors
appear to affect neuronal viability only when over-expressed in
artificial or pathological situations [11,12,13]. Nevertheless, they
are the most highly expressed isoforms in the adult mammalian
brain [14,15,16]. Only recently it has became apparent that
physiological truncated Trk receptors can have multiple functions
in mammalian development. For example, TrkB.T1 deletion in
mouse causes increased anxiety and morphological abnormalities
in basolateral amygdala neurons consistent with an independent
signaling function for this receptor. Moreover, physiological levels
of TrkB.T1 receptors are important regulators of full-length TrkB
(TrkB.FL) signaling in vivo since loss of TrkB.T1 can partially
rescue BDNF haploinsufficiency [8]. One issue that has not yet
been addressed is whether physiological levels of truncated TrkB
receptors can affect specific pathologies. For example, it has been
reported that the frontal cortex of patients with Alzheimer’s
disease has decreased BDNF and TrkB.FL expression accompa-
nied by increased truncated TrkB expression [17]. Moreover, in
ALS patients, BDNF mRNA and protein are dramatically
upregulated in muscle and total TrkB mRNA is increased in the
spinal cord. Yet, phosphorylation of the TrkB receptor is reduced
suggesting that TrkB signaling impairments in ALS are not caused
by insufficient neurotrophin supply but rather by a mechanism
affecting the TrkB response to BDNF [18,19].
Although TrkB or BDNF are not required for motoneuron
survival during development, BDNF/TrkB kinase signaling is
required for maintenance of the cholinergic phenotype of adult
motor neurons and prevents embryonic and postnatal motoneuron
cell death in a variety of experimental paradigms [reviewed in
[20]]. These observations have led to the clinical evaluation of
BDNF as a therapeutic agent in patients affected by amyotrophic
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motor neurons in the spinal cord, brainstem and motor cortex
[21]. However, to date BDNF has failed to benefit ALS patients in
clinical trials [22]. Moreover, most recently it has also been
suggested that specific deletion of TrkB.FL from motoneurons in
an ALS mouse model can be beneficial through a still unknown
mechanism [23].
Here we investigated whether the TrkB.T1 receptor isoform
affects motoneuron survival and disease progression in a widely
used ALS mouse model that carries a transgene with a human
familiar Gly
93RALA mutation in the copper/zinc superoxide
dismutase gene (SOD1
G93A or SOD1 mice) [24,25]. Our results
suggest that the deletion of TrkB.T1 prevents the loss of
motoneurons and muscle function in SOD1 mice at the early
disease stage without affecting the survival of the animals.
Moreover, treatment with the adenosine A2A receptor agonist
CGS21680, that has been shown to enhance survival of lesioned
facial motoneurons [26] leads to a similar delay in the onset of the
disease [27]. Since, CGS21680-mediated activation of TrkB
occurs independently of BDNF and it is not influenced by the
presence of TrkB.T1 at the membrane, our data suggest that
TrkB.T1 expression may affect the ability of diseased motoneurons
to respond to endogenous BDNF.
Results
TrkB.T1 deletion delays motoneuron loss in SOD1 mutant
mice
Since motoneurons express high levels of TrkB.T1 we decided
to investigate whether this receptor can limit motoneuron
responsiveness to endogenous BDNF and affect their survival in
pathological conditions. For this we employed the G93A
SOD1
mutant mouse, a well-studied mouse model of ALS. Crosses
between TrkB.T1
2/2 (T12/2) and SOD1
G93A (SOD1) mutant
mice were such to obtain control (WT), SOD1 and SOD1;T12/
2 mutant mice at 8, 12, 16 and 20 week (Wk) of age in order to
evaluate the effect of TrkB.T1 deletion on motoneuron numbers
in the SOD1 mice (Fig. 1). At 8 weeks, the SOD1 animals already
showed a small (,20%) but significant decrease in the number of
choline acetyltransferase positive (ChAT+) motor neurons, which
reached a 35% loss by 12 Wk and 40% by 16 Wk as compared to
control animals. Interestingly, SOD1;T12/2 mice start to show
a marginal, non significant loss of neurons only at 12 weeks.
However, by 16 Wk, the deletion of TrkB.T1 provided only
a partial protection since SOD1;T12/2 mice had ,15% more
motoneurons than SOD1 animals. At 20 weeks, deletion of
TrkB.T1 did not confer any protection to SOD1 mutant
motoneurons since both SOD1;T12/2 and SOD1 animals lost
about 45% motoneurons compared to WT mice (Fig. 1). Although
the loss of the cholinergic phenotype in spinal cord motoneurons
has been associated with motoneuron cell death [24,28,29], to rule
out the possibility that deletion of TrkB.T1 may affect ChAT
expression but not cell survival, we counted motoneurons from
Cresyl Violet stained sections at 12 wk of age. Again, we found
that only SOD1 mutant mice had lost a significant number of
motoneurons (,35%; p,0.05) while SOD1;T12/2 mutant mice
had a small non significant (,8%) loss of neurons
(7156.666423.37 in WT, 4588.336440.33 in SOD1;
65506345.14, in SOD1;T12/2). Taken together these data
suggest that TrkB.T1 delays the loss of SOD1 mutant motoneur-
ons and does not affect their cholinergic phenotype.
TrkB.T1 deletion affects muscle strength in SOD1 mutant
mice at disease onset
To determine whether deletion of TrkB.T1 improves muscle
strength of 8 to 20 Wk old SOD1 mice, we tested their ability to
stay on an accelerating rotarod over 5 min (Fig. 2A). At 8 weeks,
we did not observe any significant difference between groups
(Fig. 2). At 12 weeks the performance of the SOD1 mutant
animals significantly decreased by 22% compared to controls
while the SOD1;T12/2 mouse performance began to decline
(23%) by 16 weeks. However, as observed in the motoneuron
number analysis (Fig. 1), we found that by 20 weeks SOD1 and
SOD1;T12/2 mutant mice were indistinguishable in their
performance (Fig. 2A). In addition, we also compared the rate of
decline in rota-rod performance over age using Kaplan-Meier
statistics as indicated in Fig. 2B. Overall, the comparison of
performance curves between SOD1 and SOD1;T12/2 mutant
mice shows that the impairment occurs 33 days later in
SOD1;T12/2 mutant mice (Fig. 2B) suggesting that the
motoneurons rescued by TrkB.T1 deletion in the early stage of
the disease are functional.
Disease progression in SOD1;TrkB.T12/2 mutant mice
To determine whether the improvement in motor neuron
survival and muscle weakness observed after deletion of TrkB.T1
affects disease progression, we studied a cohort of SOD1 and
SOD1;T12/2 mice over their lifespan for signs and symptoms of
disease. Decline in 10% of their body weight is used as a reference
point for the early phase of the disease [30]. We found that
TrkB.T1 deletion extended the mean duration of the early phase
by 6 days in SOD1 mutant mice (a 31% increase; Fig. 3A).
However, we did not observe any difference in the mean lifespan
of the two groups (Fig. 3B). In addition to comparing the survival
curves, we evaluated the disease signs and symptoms in 20-Wk-old
animals by analyzing their locomotor activity using established
neurological scores [Fig. 3C; [28]]. Although, at this age we found
that both motoneuron numbers and rota-rod performance are
indistinguishable between SOD1 and SOD1;T12/2 mice, SOD1
transgenic mice predominantly scored in the 3–4 range, a reflection
of severe impairments in locomotor activity due to muscle
weakness and paralysis, while deletion of TrkB.T1 in these
animals improved the score to the 2–3 neurological range. These
data suggest a partial but significant improvement in muscle
function in mice at the end stage of the disease (n=14 in each
group, P,0.05; Fig. 3C).
The adenosine A2A receptor agonist CGS21680 (CGS)
delays disease onset of SOD1 mutant mice
The delayed disease onset caused by deletion of TrkB.T1 in the
SOD1 mutant mice suggests that the presence of this receptor may
affect pro-survival effects of TrkB kinase on diseased motoneurons
by limiting their responsiveness to BDNF. To further test this
hypothesis we investigated whether we could pharmacologically
affect TrkB signaling in motoneurons by using the adenosine
agonist CGS that has been shown to phosphorylate TrkB.FL in
motoneurons irrespective of the presence of BDNF and therefore
also TrkB.T1 [26,27]. SOD1 transgenic mice received daily
injections of CGS starting at 8 weeks of age before the clinical
manifestation of the disease. To evaluate whether CGS treatment
could prevent motoneuron loss in SOD1 mice, we sacrificed
a group of mice at 12 weeks and evaluated the number of
surviving motor neurons. While Cresyl Violet staining of spinal
cords revealed a significant decrease in the number of motoneur-
ons in the SOD1 mice compared to controls, SOD1 mutant mice
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39946Figure 1. Effect of TrkB.T1 deletion on motoneuron degeneration. (A) Representative immunofluorescent images of lumbar spinal cord
showing ChAT-positive motoneurons in 8-week-old animals. In comparison to age-matched WT controls, SOD1 transgenic mice show a small but
significant loss of motoneurons. This loss was prevented by deletion of TrkB.T1 in these mice (SOD1T12/2). (B) Histogram showing number of motor
neurons at 8, 12, 16 and 20 weeks. Cell counts show a progressive decrease in number of motoneurons in SOD1 animals as compared to WT controls.
The deletion of TrkB.T1 in SOD1 transgenic mice completely rescues this loss at 8 and 12 weeks. At 16 weeks this neuroprotection is partial and
significant whereas at 20 weeks it is completely lost such that both the SOD1 and SOD1T12/2 groups show severe reduction in motoneuron
numbers as compared to WT animals. The data are the Mean 6 SEM. * indicates P,0.05. N=6 in each group. Statistical analysis by ANOVA followed
by post-hoc Tukey test.
doi:10.1371/journal.pone.0039946.g001
Figure 2. Deletion of TrkB.T1 improves the motor performance of SOD1 transgenic mice on rotarod in the early phase of the
disease. (A) Histogram showing the rotarod performance of WT, SOD1 and SOD1T12/2 animals at 8, 12, 16 and 20 weeks. At 8 weeks, both SOD1
and SOD1 T12/2 animals perform similarly to controls although SOD1 mice show some impairments. With disease progression, the SOD1 transgenic
mice show a significant reduction in the amount of time spent on the rotarod at 12 and 16 weeks as compared to controls. A slight loss of motor
performance is evident only at 16 weeks in the SOD1T1 2/2 animals, although by 20 weeks the SOD1 and SOD1;T12/2 groups are
indistinguishable. The data are the Mean 6 SEM. * P,0.05. N$7. Statistical analysis by ANOVA followed by post-hoc Tukey test. (B) Kaplan-Meier
analysis of the SOD1 and SOD1T12/2 mice rotarod performance in relation to their age. Note that deletion of TrkB.T1 in the SOD1 transgenic mice
delays the impairment in rotarod performance by 34 days (81.665.87 days, n=10 in SOD1 versus 115.866.80, n=7 in SOD1 T12/2,p ,0.05).
doi:10.1371/journal.pone.0039946.g002
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those of SOD1;T12/2 mutant and WT mice (Fig. 4A).
Furthermore, analysis of muscle strength by rota-rod analysis
showed a delay in the development of rota-rod impairment in the
CGS treated SOD1 mice by 8 days when compared to the
vehicle-treated SOD1 controls (Figure 4B) suggesting that CGS
could affect both survival and function of SOD1 motoneurons.
Moreover, CGS treatment also prolongs the early disease stage by
12 days (Figure 4C). However, as seen in the SOD1;T12/2
mutant mice, protection of motoneurons by CGS disappeared in
the late stages of the disease as CGS treated SOD1 mutant mice
had no increased life span compared to that of controls (Figure 4D).
Discussion
In this study, we tested the hypothesis that the presence of
endogenous truncated TrkB limits BDNF pro-survival effects on
diseased motoneurons. We found that deletion of TrkB.T1
receptors from the SOD1
G93A mouse model of ALS delays disease
onset without extending the lifespan of the animals. Moreover, we
showed that the adenosine A2A receptor agonist CGS, that causes
TrkB phosphorylation independently of BDNF by a transactivation
mechanism, has an effect similar to removing TrkB.T1 in this ALS
mouse model.
The pro-survival role of BDNF on lesioned facial and sciatic
nerves as well as its protective effect, in combination with CNTF,
on degenerating motoneurons in the wobbler mutant model has
lead to its use as a potential therapeutic agent in neurodegener-
ative motoneuron diseases [31]. However, in clinical trials BDNF
has failed to show any beneficial effect [reviewed in [22]].
Although this failure has been attributed to factors such as
inadequate dosage, short half-life and limited bioavailability, even
a subsequent trial with intrathecal infusion of BDNF, aimed at
improving the bioavailability of BDNF, also failed. Thus, the
precise reasons for the lack of efficacy of BDNF in the clinic are
still elusive. Curiously, the activity and/or appropriate delivery of
BDNF has never been evaluated in animal models of ALS and,
although insufficient neurotrophic support has been included as
one possible reason for motoneuron degeneration, the levels of
BDNF and its receptor TrkB are not decreased in ALS. In fact,
some studies have shown that BDNF and total TrkB levels are
either increased or unaltered in the CNS of ALS patients. Despite
this, some studies have reported a decrease in TrkB phosphory-
lation [18,19,32,33]. These observations suggest that while
a primary deficiency of BDNF may not be a cause for the
Figure 3. Disease progression and survival of SOD1 and
SOD1;T12/2 mice. Histograms from Kaplan-Meier analysis showing
the duration of the early phase (A) and the end stage (B) of the disease,
as well as the neurological scoring (C) of SOD1 and SOD1;T12/2 mice.
Deletion of TrkB.T1 delays the early phase of disease progression by
6 days (19.261.25 days, n=30 in SOD1 animals versus 25.262.09 days
n=21 in SOD1;T12/2,P ,0.05; A). Note the similar life span between
groups (B) despite the improvement in the overall neurological score at
20 wk in the SOD1;T12/2 compared to the SOD1 mutant mice (C;
P,0.05).
doi:10.1371/journal.pone.0039946.g003
Figure 4. The adenosine A2A receptor agonist CGS21680
delays disease onset in SOD1 mutant mice. CGS treatment at
12 weeks of age significantly rescues motor neuron degeneration in
SOD1 mice (A; p,0.05). Analysis of rotarod data showing that
treatment of SOD1 mice with CGS delays the impairment in rotarod
performance by 7 days compared to untreated SOD1 mice (B; Kaplan
Meier Analysis, p,0.01). CGS treatment also prolongs the duration of
the early phase of the disease by 12 days (C; p,0.05) although it does
not affect the mean life span of the SOD1 mutant animals (D).
doi:10.1371/journal.pone.0039946.g004
Role of TrkB.T1 in Diseased Motoneurons
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39946reduction in TrkB activity, alterations of the level of TrkB receptor
isoforms or in downstream signaling events could underlie
motoneuron losses. Our data support this hypothesis since
removing physiological TrkB.T1 receptors delays the onset of
motoneuron losses and functional impairments. Therefore, de-
velopmental up-regulation of TrkB.T1 in the adult CNS, not only
influences TrkB signaling in normal physiological conditions but
also the response of injured motoneurons to BDNF. Recently, it
has been reported that TrkB.T1 up-regulation occurs under
conditions of neuronal insults such as excitotoxicity and cerebral
ischemia [34,35]. Moreover, TrkB.T1 is up-regulated in neuro-
degenerative disorders such as Alzheimer’s disease [17] suggesting
that imbalances in expression between the TrkB.FL and truncated
TrkB isoforms makes BDNF signaling ineffective and contributes
to neuronal damage [35]. In accordance with this hypothesis,
over-expression of TrkB.T1 induces motor neuron death and in
the CNS worsens the infarct area after cerebral ischemia [11,36].
However, whether physiological levels of TrkB.T1 can influence
neuronal survival during injury has not been tested. Our data now
support the idea that endogenous TrkB.T1 negatively affects
neuron survival in neurodegenerative disorders.
Moreover, our data suggest that delivery of neurotrophins may
not be sufficient to promote neuronal survival of injured neurons
because TrkB.T1 limits neurons responsiveness to BDNF. In-
terestingly, axotomized retina ganglionic cells survive indefinitely
when BDNF is supplied in combination with TrkB overexpression,
but survive only for a short period if provided with BDNF alone
[37].
While in vitro experiments and artificial overexpression
experiments have limitations, our study strongly suggests that
physiological or pathological imbalances in TrkB receptor isoform
levels can affect motoneuron survival. It will be of interest to
investigate whether ALS patients with increased total TrkB, and
decreased TrkB phosphorylation have imbalances in TrkB isoform
expression levels. The recent identification of ALS patients with
mutations in the TDP-43 and FUS genes, that appear to be
involved in splicing regulation suggest that this could be
a possibility if, for example, TDP-43 and/or FUS can affect TrkB
splicing [38]. Interestingly, in the TS16 trisomic mouse model the
triplication of a number of genes, including some controlling
splicing, causes an upregulation of TrkB.T1 receptors responsible
for increased cortical neuronal cell death and hippocampal neuron
vulnerability to BDNF deficiency [12]. New studies aimed at
identifying whether ALS patients have higher levels of truncated
TrkB receptors and whether mutations in the TDP-43 and FUS
genes affect TrkB splicing should help clarify this issue.
Despite the decrease in motor neuron losses and amelioration in
muscle function at the early stage of the disease, deletion of
TrkB.T1 failed to increase the mean life span of the SOD1 mutant
animals. ALS is a complex neurodegenerative disease for which
there is little information about the molecular mechanism causing
motoneurons to degenerate [39]. Even the pathogenic effect of the
SOD1 mutant protein on motoneurons is still unclear. However, it
has been shown that there is a direct correlation between the level
of SOD1 mutant protein and the severity of the phenotype
suggesting a toxic effect of the mutated protein [39,40]. Contrary
to the SOD1 familial cases, which carry only one allele of the
mutant gene, the ALS mouse model used in the present study
carries a high transgene copy number and shows an extremely
rapid progression of disease. Therefore, the extreme toxicity of the
mutant SOD1 protein produced at such a high level might hide
small but significant effects on survival that could be detected if less
SOD1 mutant protein was produced. The present study aimed to
increase the endogenous BDNF-TrkB.FL signaling by deleting the
putative dominant/negative function of TrkB.T1 without pro-
viding exogenous neurotrophin support. In such a scenario, it is
likely that deletion of TrkB.T1, which provides neuroprotection in
the early stages of the disease is unable to sustain its effects with the
increasing load of SOD1 mutant protein that occurs at later stages.
Alternatively, the increased trophic effect could be limited to
motoneurons of the limbs and not of respiratory muscles, which
would lead to an overall improvement of the clinical manifestation
of the disease in both the early and late stages of the disease
(Fig. 3C) but to a failure in the overall extension of the animal
lifespan. A differential effect on specific motoneuron populations
could be explained by different levels of expression of TrkB.T1 in
distinct motoneuron pools. For example, TrkB.T1 deletion would
have a more significant impact on BDNF signaling in a neuronal
population normally expressing high levels of the receptor
compared to the response of a neuronal population expressing
lower levels of TrkB.T1. However, to date it is still unknown
whether different motoneuron pools express TrkB.T1 at different
levels.
The report that TrkB.T1 affects Ca++ signaling suggests that
imbalances in the TrkB.T1 receptor level may affect motoneuron
survival by altering intracellular Ca++ levels [12,41]. Dysregula-
tion of calcium homeostasis in spinal motoneurons of SOD1
mutant mice has already been reported [42,43]. Moreover, it has
also been shown that spinal motor neurons have diminished
calcium-buffering capacity due to their low expression of calcium
binding proteins, making them more vulnerable in disease states
like ALS [44]. Thus, it is conceivable that deletion of TrkB.T1
might improve calcium homeostasis in SOD1 mutant mice
contributing to the rescue of spinal motoneuron death in the
early stages of disease. In this scenario, the delay in the onset of the
disease in SOD1 mutant mice caused by deletion of TrkB.T1 and
CGS treatment could be due to different mechanisms: one based
on Ca++ level regulation by TrkB.T1 and the other based on the
increased activation of TrkB.FL signaling by transactivation.
One of the most surprising findings of this study was the positive
effect, at least during the early stage of the disease, caused by
TrkB.T1 removal on motoneuron survival without the need to
apply exogenous BDNF. Thus, these data support the relevance of
physiological levels of TrkB.T1 receptors on the control of TrkB
signaling promoting the survival of diseased motoneurons. While
our genetic strategy (i.e deletion of TrkB.T1) provides the proof-of-
principle that targeting the pathways downstream of BDNF can be
one important factor in achieving motoneuron neuroprotection,
our results also suggest that it may be more useful to promote
activation of TrkB intracellularly rather than by using BDNF
mimetics. In fact, the use of the adenosine A2a receptor agonist
CGS achieved the same results as deleting TrkB.T1. Of course, it
is also possible that besides transactivating TrkB, activation of the
adenosine receptor could have an effect by promoting cAMP
signaling, that, in turn, induces the release of neurotrophic factors
including BDNF, NGF and GDNF [45]. If this is the case,
treatment of SOD1 mutant mice with CGS, coupled with the
TrkB.T1 deletion may have additive effects and address this issue.
Treatment of SOD1
G93A mutant mice with CGS delays
motoneurons death similarly to TrkB.T1 deletion suggesting that
the pro-survival effect seen in motoneurons by removing TrkB.T1
is cell autonomous. In fact, CGS causes activation of TrkB.FL that
is expressed exclusively in motoneurons and TrkB.T1 removal
may improve TrkB.FL activation bypassing TrkB.T1 dominant/
negative or neurotrophin-sequestering activity. However, since
TrkB.T1 is expressed in both motoneurons as well as glia cells, in
the future it will be critical to investigate the effect of deletion of
this receptor isoform in specific cell types to establish the cell-
Role of TrkB.T1 in Diseased Motoneurons
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model of experimental autoimmune encephalomyelitis (EAE) have
shown that deletion of TrkB from glia cells renders these mice
more resistant to EAE susceptibility and severity. Mechanistically,
TrkB.T1 in astrocytes appears responsible for the production of
nitric oxide which in turns induces neuronal degeneration and
apoptosis [46].
Despite the repeated therapeutic failure of neurotrophic factors
in clinical trials, recent experimental and clinical efforts are aimed
at improving the level of neurotrophic factors in motoneurons by
gene therapy and/or by developing novel systems to deliver drugs
[47]. Additional efforts are also focusing on the effects of the
combinatorial use of different neurotrophic factors. Irrespective,
our data suggests that a better understanding of the signal
transduction pathways downstream of neurotrophins and of
modalities to activate these pathways may be more critical than
identifying strategies for delivering exogenous neurotrophins.
Materials and Methods
Animals
SOD1
G93A [B6SJL-TGN(SOD1-G93A)1GUR/J; 002726]
mice were acquired from The Jackson Laboratory (Bar Harbor,
ME) and crossed to TrkB.T1 knockout mice backcrossed on C57/
B16J background for at least 10 generations [12]. All experiments
were conducted with the experimenter blind to the genotype of the
animals. Protocols followed the National Institutes of Health
Guidelines for animal care and use, and were approved by the
NCI-Frederick ACUC committee.
Motor neuron survival and stereology
Mice were anesthetized and perfused transcardially with 0.9%
NaCl followed by 4% paraformaldehyde. The lumbar region of
the spinal cord (L1–L5) was removed and 50-mm transverse
sections were cut on a cryostat. Every 10
th section (17–20 sections
total per animal) was collected for analysis. Motoneurons were
visualized by immunofluorescent staining for Choline acetyltrans-
ferase (ChAT, 1:500 Millipore) and by Cresyl Violet staining and
counted by the stereological modified optical fractionator method
multiplying the number of counted neurons per section with the
sampling fraction.
Evaluation of motor performance
Muscle strength and coordination were assessed by an
accelerating rota-rod (Ugo Basile, Italy) that rotates from 4 to 40
RPM over 5 min [29]. After two training trials of 5 min each (at
7 weeks) animals were run three times a week (from 8 weeks on)
and the duration for which the animal stayed on the rota-rod
without falling (up to a maximum of 300 seconds) was recorded.
We also determined the age at which the performance of the
animals fell below 150 seconds in two successive trials, and this
time point was taken as an index of rota-rod impairment.
Analysis of disease progression and survival
To monitor the progression of the disease we used two different
parameters: early progression of disease and end-stage disease in
the animals. Starting at 8 weeks of age, animals were weighed
three times weekly. Given that animals start losing weight with
disease progression, we defined the early progression of disease as
the duration between the time of peak weight and the time when
animals lose 10% of peak weight due to muscle atrophy. End-stage
was defined as the age of actual death of the animal or the age at
which paralysis rendered the animal unable to right itself within
20 seconds when placed on its side [30].
Neurological Scoring
Animals were scored for disease signs and symptoms at
20 weeks based on the following scale [28]:
0= normal functions, no sign of disease onset.
1= distal muscle (paw) weakness of one limb.
2= distal muscle weakness of two limbs, slight wobble when
walking.
3= weakness of proximal muscle (leg) of one limb plus weakness
in two distal muscles, clear wobble when walking.
4= both hind limbs paralyzed with dragging of hind limbs.
5= animal is immobile.
CGS21680 treatment
The adenosine A2A receptor agonist CGS21680 was purchased
from Tocris (USA) or custom synthesized from ChemieTek (IN,
USA). CGS21680 was dissolved in 5% DMSO prior to use.
Starting at 8 weeks of age animals received a single daily
intraperitoneal injection of CGS21680 or vehicle (5% DMSO)
and were sacrificed at different time points depending on the
experiments. The dose of CGS21680 (5mg/kg) was determined on
the basis of our pilot study and other studies [27,48].
Statistical Analysis
GraphPad software (InStat and Prism) was used for all statistical
analysis. Comparisons of motor neuron numbers and rota-rod
performance between the groups at different ages was done by
ANOVA followed by post-hoc Tukey-Kramer Multiple compar-
ison test or Dunn test. Survival analysis (rota-rod impairment,
early progression of disease and end-stage) was subjected to
Kaplan-Meier Statistics. A Log rank P value was calculated to
compare the survival curves. Neurological scores were compared
by Mann-Whitney test. Data are represented as Mean 6 SEM.
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